NASDAQ:GLYC GlycoMimetics Q1 2025 Earnings Report $0.25 0.00 (-1.12%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$0.25 0.00 (0.00%) As of 05/16/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast GlycoMimetics EPS ResultsActual EPS-$0.04Consensus EPS -$0.05Beat/MissBeat by +$0.01One Year Ago EPSN/AGlycoMimetics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGlycoMimetics Announcement DetailsQuarterQ1 2025Date5/14/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) GlycoMimetics Earnings HeadlinesGlycoMimetics (NASDAQ:GLYC) Stock Crosses Below Two Hundred Day Moving Average - Time to Sell?May 17 at 4:05 AM | americanbankingnews.comGlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.comMay 17 at 3:21 AM | americanbankingnews.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.May 18, 2025 | Paradigm Press (Ad)GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYCMay 16 at 1:55 PM | businesswire.comGlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.comMay 9, 2025 | americanbankingnews.comCrescent Biopharma Appoints David Lubner to Board of DirectorsApril 28, 2025 | globenewswire.comSee More GlycoMimetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like GlycoMimetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GlycoMimetics and other key companies, straight to your email. Email Address About GlycoMimeticsGlycoMimetics (NASDAQ:GLYC), a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.View GlycoMimetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum Holds Upcoming Earnings PDD (5/20/2025)Palo Alto Networks (5/20/2025)Synopsys (5/20/2025)Home Depot (5/20/2025)Mitsubishi UFJ Financial Group (5/21/2025)Sumitomo Mitsui Financial Group (5/21/2025)Medtronic (5/21/2025)TJX Companies (5/21/2025)Snowflake (5/21/2025)Lowe's Companies (5/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
